Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients

Basit Öğe Kaydı
dc.contributor.authorPamuk, O. N.
dc.contributor.authorOnat, A. M.
dc.contributor.authorDonmez, S.
dc.contributor.authorMengus, C.
dc.contributor.authorKisacik, B.
dc.date.accessioned2024-06-12T11:15:57Z
dc.date.available2024-06-12T11:15:57Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Systemic lupus erythematosus (SLE) patients have seriously impaired quality of life (QoL). In addition to activity and damage indices used in the past, tools to evaluate QoL in SLE have been developed in recent years. In this study, we test the validity of the Turkish version of the Lupus-QoL (LupusQoL-TR) score, and investigate its association with clinical findings and activity indices. Methods A total of 132 patients diagnosed with SLE according to ACR 1997 criteria were included. The clinical and demographic features, and biochemical data were retrieved from hospital records. SLE Disease Activity Index (SLEDAI) and damage score (SLICC-ACR) were determined at the time of administration of Lupus-QoL questionnaire. The Lupus-QoL includes 34 questions divided into eight domains. We reevaluated the LupusQoL-TR and pretested its understandability. SLE patients were concomitantly administered the LupusQoL-TR and generic SF-36. Internal consistency, test-retest reliability, convergent and discriminant validity were calculated. Results The mean age of our SLE patients was 37.912.8 years. Internal consistency reliability ranged from 0.88 to 0.93, and test-retest reliability from 0.84 to 0.94. LupusQoL-related domains in SF-36 were correlated (from 0.66 to 0.74). Most LupusQoL-TR domains, except planning, were able to discriminate between active and inactive SLE groups. Scores in all domains of the LupusQoL-TR were found to be discriminative for patients with and without damage according to SLICC-ACR score. Conclusion The LupusQoL-TR was found to be a valid patient-reported outcome measure method when evaluating QoL in Turkish SLE patients.en_US
dc.identifier.doi10.1177/0961203314565412
dc.identifier.endpage821en_US
dc.identifier.issn0961-2033
dc.identifier.issn1477-0962
dc.identifier.issue8en_US
dc.identifier.pmid25542903en_US
dc.identifier.scopus2-s2.0-84930921910en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage816en_US
dc.identifier.urihttps://doi.org/10.1177/0961203314565412
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24136
dc.identifier.volume24en_US
dc.identifier.wosWOS:000356233900005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofLupusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.subjectLupusqol-TRen_US
dc.subjectQuality Of Lifeen_US
dc.subjectHealth Outcome Measureen_US
dc.subjectValidationen_US
dc.subjectQuality-Of-Lifeen_US
dc.subjectDisease-Activityen_US
dc.subjectValidationen_US
dc.subjectManifestationsen_US
dc.subjectSurvivalen_US
dc.subjectCohorten_US
dc.titleValidity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu